FILING ANALYSIS · MONDAY, NOVEMBER 9
ImmunityBio, Inc. IBRX — 8-K: Results of Operations and Financial Condition
positive
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, and a 92% increase in year-to-date revenue to $143.6 million, driven by continued adoption of ANKTIVA among U.S. urologists and strong market access, with the company also announcing expanded FDA approval and global expansion of ANKTIVA in non-muscle invasive bladder cancer (NMIBC).
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →